32934 Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices 

vaccine, dengue vaccine, ebola vaccine, 

hepatitis vaccines, herpes zoster 

vaccines, influenza vaccines, 

orthopoxvirus vaccine, pneumococcal 

vaccine, rabies vaccine and tickborne 

encephalitis vaccine. Recommendation 

votes on dengue vaccine, ebola vaccine, 

influenza vaccines and rabies vaccine 

are scheduled. Vaccines for Children 

(VFC) votes on dengue vaccine and 

influenza vaccines are scheduled. 

Agenda items are subject to change as 

priorities dictate. For more information 

on the meeting agenda visit https://

www.cdc.gov/vaccines/acip/meetings/ 

meetings-info.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web; for more information on ACIP 

please visit the ACIP website: http://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the June 23–25, 

2021, ACIP meeting must submit a 

request at http://www.cdc.gov/vaccines/ 

acip/meetings/ no later than 11:59 p.m., 

EDT, June 18, 2021, according to the 

instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by June 21, 2021. To accommodate the 

significant interest in participation in 

the oral public comment session of 

ACIP meetings, each speaker will be 

limited to 3 minutes, and each speaker 

may only speak once per meeting. 

Written Public Comment: The docket 

will be opened to receive written 

comments on June 1, 2021. Written 

comments must be received on or before 

June 25, 2021. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–13120 Filed 6–22–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—CE21–006: 

Rigorously Evaluating Programs and 

Policies To Prevent Child Sexual 

Abuse (CSA); Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP)—CE21– 

006: Rigorously Evaluating Programs 

and Policies to Prevent Child Sexual 

Abuse (CSA); July 13–14, 2021, 8:30 

a.m.–5:00 p.m., EDT. 

The videoconference meeting was 

published in the Federal Register on 

March 29, 2021, Volume 86, Number 58, 

page 16369. 

The meeting is being amended to 

update the contact person and should 

read as follows: 

FOR FURTHER INFORMATION CONTACT: 

Aisha Wilkes, M.P.H., Scientific Review 

Officer, National Center for Injury 

Prevention and Control, CDC, 4770 

Buford Highway NE, Mailstop S106–9, 

Atlanta, Georgia 30341, Telephone: 

(404) 639–6473; Email: awilkes@

cdc.gov. 

The meeting is closed to the public. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–13121 Filed 6–22–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Injury Prevention 

and Control, (BSC, NCIPC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Board of Scientific Counselors, 

National Center for Injury Prevention 

and Control (BSC, NCIPC). This meeting 

is partially open to the public. There 

will be 15 minutes allotted for public 

comments at the end of the open session 

from 11:40 a.m., to 11:55 p.m., EDT. 

DATES: The meeting will be held on July 

29, 2021, from 10:00 a.m. to 12:00 p.m., 

EDT (OPEN); and from 12:30 p.m., to 

4:15 p.m., EDT (CLOSED). 

ADDRESSES: Open Session: Webinar, 

Atlanta, Georgia. All participants must 

register using the link provided to 

attend the open meeting: https://

dceproductions.zoom.us/webinar/ 

register/wn_cz3nu0zfsg29fiojefau8q. 

Closed Session: Teleconference. 

FOR FURTHER INFORMATION CONTACT: 

Gwendolyn H. Cattledge, Ph.D., 

M.S.E.H., Deputy Associate Director for 

Science, NCIPC, CDC, 4770 Buford 

Highway NE, Mailstop S106–9, Atlanta, 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices 32935 

GA 30341, Telephone: (770) 488–3953; 

Email: NCIPCBSC@cdc.gov. 

SUPPLEMENTARY INFORMATION: Portions 

of the meeting as designated above will 

be closed to the public in accordance 

with provisions set forth in Section 

552b(c)(4) and (6), Title 5 U.S.C., and 

the Determination of the Director, 

Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, 

CDC, pursuant to Public Law 92–463 (5 

U.S.C. App.). 

Purpose: The Board will: (1) Conduct, 

encourage, cooperate with, and assist 

other appropriate public health 

authorities, scientific institutions, and 

scientists in the conduct of research, 

investigations, experiments, 

demonstrations, and studies relating to 

the causes, diagnosis, treatment, control, 

and prevention of physical and mental 

diseases, and other impairments; (2) 

assist States and their political 

subdivisions in preventing and 

suppressing communicable and noncommunicable diseases and other 

preventable conditions and in 

promoting health and well-being; and 

(3) conduct and assist in research and 

control activities related to injury. The 

BSC, NCIPC makes recommendations 

regarding policies, strategies, objectives, 

and priorities; reviews progress toward 

injury prevention goals; and provides 

evidence in injury prevention-related 

research and programs. The Board also 

provides advice on the appropriate 

balance of intramural and extramural 

research, and the structure, progress, 

and performance of intramural 

programs. The Board is designed to 

provide guidance on extramural 

scientific program matters, including 

the: (1) Review of extramural research 

concepts for funding opportunity 

announcements; (2) conduct of 

Secondary Peer Review of extramural 

research grants, cooperative agreements, 

and contracts applications received in 

response to funding opportunity 

announcements as they relate to the 

Center’s programmatic balance and 

mission; (3) submission of secondary 

review recommendations to the Center 

Director of applications to be considered 

for funding support; (4) review of 

research portfolios, and (5) review of 

program proposals. 

Matters To Be Considered: The open 

portion of the agenda will include 

discussion on NCIPC Research Priorities 

for Addressing Adverse Childhood 

Experiences. The closed portion of the 

agenda will focus on the Secondary Peer 

Review of extramural research grant 

applications received in response to 

three Notice of Funding Opportunities 

(NOFOs): (1) RFA–CE–21–001— 

‘‘Rigorous Evaluation of Policies for 

their Impacts on the Primary Prevention 

of Multiple Forms of Violence’’; (2) 

RFA–CE–21–003—‘‘Grants to Support 

New Investigators in Conducting 

Research Related to Preventing 

Interpersonal Violence Impacting 

Children and Youth’’; and (3) RFA–CE– 

21–004—‘‘Research Grants for 

Preventing Violence and ViolenceRelated Injury (R01)’’; as well as PHS 

2020 Omnibus Solicitation of the NIH, 

CDC and FDA for Small Business 

Innovation Research Grant Applications 

(Parent SBIR [R43/R44] Clinical Trial 

Not Allowed). Agenda items are subject 

to change as priorities dictate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–13119 Filed 6–22–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10137 and CMS– 

10174] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

August 23, 2021. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number: ll, Room C4–26–05, 

7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

website address at https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10137 Solicitation for 

Applications for Medicare 

Prescription Drug Plan 2023 Contracts 

CMS–10174 Collection of Prescription 

Drug Data from MA–PD, PDP and 

Fallout Plans/Sponsors for Medicare 

Part D Payments 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 


jbell on DSKJLSW7X2PROD with NOTICES